Get the Stockscreener App
1.58
5.39%
-0.09
Quince Therapeutics Inc Stock (QNCX) Forecast
The Quince Therapeutics Inc (QNCX) stock price forecast for the next 30 days is generally negative, with an average analyst price target of $1.2702, representing a -19.61% decrease from the current price of $1.58. The highest analyst price target is $1.4147, and the lowest is $1.1257.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month QNCX Price Target
Average 1.6714
(+5.79% Upside)
Is Quince Therapeutics Inc (QNCX) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 43.92 | Neutral |
| STOCH(9,6) | 43.03 | Neutral |
| STOCHRSI(14) | 69.64 | Neutral |
| MACD(12,26) | -0.0548 | Buy |
| ADX(14) | 16.71 | Neutral |
| William %R | -53.86 | Neutral |
| CCI(14) | -2.8621 | Neutral |
Buy: 1
Sell: 0
Neutral: 6
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
1.616
Sell
|
1.6175
Sell
|
| MA20 |
1.6523
Sell
|
1.6604
Sell
|
| MA50 |
1.8231
Sell
|
1.6732
Sell
|
| MA100 |
1.4621
Buy
|
1.5133
Buy
|
| MA200 |
1.1213
Buy
|
1.3217
Buy
|
Buy: 4
Sell: 6
Neutral: 0
Summary: Sell
According to our latest analysis, QNCX could be considered a Neutral, with 17 technical analysis indicators signaling 5 Buy signals, 6 signaling Sell signals and 6 Neutral signals. This suggests that investors should exercise caution when entering new positions on QNCX, as the market is likely to remain volatile in the near term.
- RSI (Relative Strength Index): The RSI(14) value of 43.92 indicates that QNCX is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 43.03 indicates that QNCX is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 69.64 indicates that QNCX is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- ADX (Average Directional Index): The ADX value of The ADX value of 16.71 indicates that there is no clear directional movement, and the market may be ranging or moving sideways.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of -2.8621 indicates that QNCX is not in oversold or overbought territory. It suggests a neutral sentiment in the short term.
Long-term QNCX price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Quince Therapeutics Inc financial reports and earnings history, Quince Therapeutics Inc (QNCX) stock could reach $2.2309 by 2030, $4.0726 by 2040 and $5.1617 by 2050. See the projected annual prices until 2050 of the Quince Therapeutics Inc stock below:
- Quince Therapeutics Inc (QNCX) is expected to reach an average price of $3.0437 in 2035, with a high prediction of $3.1859 and a low estimate of $2.8759. This indicates an $92.64% rise from the last recorded price of $1.58.
- Quince Therapeutics Inc (QNCX) stock is projected to chart a bullish course in 2040, with an average price target of $3.6888, representing an $133.47% surge from its current level. The forecast ranges from a conservative $2.9314 to a sky-high $4.0726.
- Our analysts predict Quince Therapeutics Inc (QNCX) to jump 161.78% by 2045, soaring from $4.1261 to an average price of $4.1361, potentially reaching $4.3284. While $4.1261 is the low estimate, the potential upside is significant.
- Quince Therapeutics Inc (QNCX) stock is expected to climb by 2050, reaching an average of $5.0011, a $216.52% jump from its current level. However, a wide range of estimates exists, with high and low targets of $5.1617 and $4.7027, respectively, highlighting the market's uncertainty.
Quince Therapeutics Inc Stock (QNCX) Year by Year Forecast
Quince Therapeutics Inc Stock (QNCX) Price Forecast for 2025
Quince Therapeutics Inc Stock (QNCX) is expected to reach an average price of $1.641 in 2025, with a high prediction of $2.2596 and a low estimate of $1.0223. This indicates an +3.86% rise from the last recorded price of $1.58.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| March, 2025 | $1.2352 | $1.1257 | $1.4147 | -21.83% |
| April, 2025 | $1.4275 | $1.1756 | $1.6167 | -9.65% |
| May, 2025 | $1.5194 | $1.3785 | $1.5994 | -3.83% |
| June, 2025 | $1.3513 | $1.2708 | $1.6099 | -14.47% |
| July, 2025 | $1.2437 | $1.0832 | $1.4423 | -21.29% |
| August, 2025 | $1.1568 | $1.1169 | $1.3146 | -26.78% |
| September, 2025 | $1.8706 | $1.1288 | $2.2596 | +18.39% |
| October, 2025 | $1.9853 | $1.7153 | $2.0744 | +25.65% |
| November, 2025 | $1.9391 | $1.6891 | $2.0763 | +22.73% |
| December, 2025 | $1.9738 | $1.741 | $2.0438 | +24.93% |
Quince Therapeutics Inc Stock (QNCX) Price Forecast for 2026
The predicted value for Quince Therapeutics Inc (QNCX) in 2026 is set at an average of $1.6388. Estimates vary from a peak of $2.073 to a trough of $1.2046, indicating an +3.72% surge from the present price of $1.58.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $1.5576 | $1.4257 | $2.0448 | -1.42% |
| February, 2026 | $1.6614 | $1.5386 | $1.6914 | +5.15% |
| March, 2026 | $1.5052 | $1.4652 | $1.7142 | -4.74% |
| April, 2026 | $1.33 | $1.2899 | $1.5861 | -15.82% |
| May, 2026 | $1.2237 | $1.2048 | $1.3628 | -22.55% |
| June, 2026 | $1.3325 | $1.2046 | $1.4037 | -15.67% |
| July, 2026 | $1.7422 | $1.3184 | $1.7722 | +10.27% |
| August, 2026 | $1.706 | $1.5151 | $1.8033 | +7.97% |
| September, 2026 | $1.6607 | $1.5669 | $1.7998 | +5.11% |
| October, 2026 | $1.4445 | $1.4345 | $1.6567 | -8.58% |
| November, 2026 | $1.4483 | $1.2764 | $1.5255 | -8.34% |
| December, 2026 | $2.053 | $1.2803 | $2.073 | +29.94% |
Quince Therapeutics Inc Stock (QNCX) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Quince Therapeutics Inc (QNCX) is $1.9056, with a high forecast of $2.4245 and a low forecast of $1.3866. This indicates an +20.60% increase from the last price of $1.58.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $2.0287 | $1.9259 | $2.4245 | +28.40% |
| February, 2027 | $1.9644 | $1.883 | $2.2444 | +24.33% |
| March, 2027 | $2.0515 | $1.8586 | $2.1686 | +29.84% |
| April, 2027 | $2.0972 | $1.9243 | $2.2172 | +32.73% |
| May, 2027 | $1.7428 | $1.5986 | $2.0086 | +10.31% |
| June, 2027 | $1.7999 | $1.7457 | $1.8799 | +13.92% |
| July, 2027 | $1.6056 | $1.5556 | $1.8914 | +1.62% |
| August, 2027 | $1.5119 | $1.4699 | $1.677 | -4.31% |
| September, 2027 | $1.4384 | $1.3866 | $1.5441 | -8.96% |
| October, 2027 | $1.6841 | $1.4598 | $1.7841 | +6.59% |
| November, 2027 | $1.9097 | $1.5469 | $1.9898 | +20.87% |
| December, 2027 | $1.8468 | $1.7026 | $1.9554 | +16.89% |
Quince Therapeutics Inc Stock (QNCX) Price Forecast for 2028
In 2028, Quince Therapeutics Inc (QNCX) is projected to reach an average price of $2.0165, with a high projection of $2.5893 and a low estimate of $1.4437. This indicates an +27.63% rise from the last price of $1.58.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $1.7375 | $1.6525 | $1.9897 | +9.97% |
| February, 2028 | $1.6032 | $1.5882 | $1.8282 | +1.47% |
| March, 2028 | $1.5867 | $1.4696 | $1.7039 | +0.43% |
| April, 2028 | $2.2993 | $1.4437 | $2.5893 | +45.52% |
| May, 2028 | $2.2087 | $2.0912 | $2.4087 | +39.79% |
| June, 2028 | $2.1963 | $2.0506 | $2.4125 | +39.01% |
| July, 2028 | $2.1889 | $2.0282 | $2.3382 | +38.54% |
| August, 2028 | $1.8933 | $1.7714 | $2.3896 | +19.83% |
| September, 2028 | $1.9609 | $1.8652 | $2.039 | +24.11% |
| October, 2028 | $1.9585 | $1.8945 | $2.0685 | +23.95% |
| November, 2028 | $1.707 | $1.6829 | $2.0204 | +8.04% |
| December, 2028 | $1.6271 | $1.6265 | $1.7798 | +2.98% |
Quince Therapeutics Inc Stock (QNCX) Price Forecast for 2029
The 2029 price forecast for Quince Therapeutics Inc Stock (QNCX) is $2.1613 on average, with a high prediction of $2.7541 and a low estimate of $1.5685. This represents an +36.79% increase from the previous price of $1.58.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $1.70 | $1.5685 | $1.7712 | +7.59% |
| February, 2029 | $1.8925 | $1.6869 | $1.9688 | +19.78% |
| March, 2029 | $1.9901 | $1.8444 | $2.1764 | +25.96% |
| April, 2029 | $2.0877 | $1.9439 | $2.1677 | +32.13% |
| May, 2029 | $1.9671 | $1.8434 | $2.1796 | +24.50% |
| June, 2029 | $1.8247 | $1.6628 | $2.019 | +15.49% |
| July, 2029 | $1.647 | $1.6071 | $1.8985 | +4.24% |
| August, 2029 | $2.4088 | $1.6205 | $2.7541 | +52.46% |
| September, 2029 | $2.4883 | $2.2183 | $2.5759 | +57.49% |
| October, 2029 | $2.4001 | $2.1977 | $2.5807 | +51.91% |
| November, 2029 | $2.4896 | $2.2525 | $2.5596 | +57.57% |
| December, 2029 | $2.079 | $1.9443 | $2.5619 | +31.58% |
Quince Therapeutics Inc Stock (QNCX) Price Forecast for 2030
Quince Therapeutics Inc Stock (QNCX) is expected to reach an average price of $2.3346 in 2030, with a high forecast of $2.9189 and a low forecast of $1.7503. This signifies an +47.76% surge from the last price of $1.58.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $2.1809 | $2.0614 | $2.2309 | +38.03% |
| February, 2030 | $2.0103 | $1.9503 | $2.2456 | +27.24% |
| March, 2030 | $1.8699 | $1.8298 | $2.1027 | +18.35% |
| April, 2030 | $1.7692 | $1.7503 | $1.9069 | +11.98% |
| May, 2030 | $2.1011 | $1.7516 | $2.1161 | +32.98% |
| June, 2030 | $2.3005 | $1.9182 | $2.3305 | +45.60% |
| July, 2030 | $2.2424 | $2.0776 | $2.363 | +41.92% |
| August, 2030 | $2.2318 | $2.1347 | $2.3695 | +41.25% |
| September, 2030 | $2.0213 | $2.0113 | $2.2292 | +27.93% |
| October, 2030 | $2.0431 | $1.856 | $2.1036 | +29.31% |
| November, 2030 | $2.5461 | $1.7705 | $2.5661 | +61.14% |
| December, 2030 | $2.5274 | $2.4218 | $2.9189 | +59.96% |
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):